Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.44 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817552 | 0.88 | GPR84 (0.67) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL28022735 | 0.79 | GPR84 (0.52) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL28022723 | 0.79 | GPR84 (0.52) | GPR84FFAR1FFAR4MAPTLCK | |
| Acetic Acid SCHEMBL27472146 | 0.77 | GPR84 (0.60) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL30550507 | 0.76 | GPR84 (0.57) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL6154159 | 0.76 | GPR84 (0.57) | GPR84FFAR1FFAR4MAPTLCK | |
| SCHEMBL15527770 | 0.76 | FFAR1 (0.68) | GPR84FFAR1FFAR4 | |
| SCHEMBL19693898 | 0.76 | FFAR1 (0.68) | GPR84FFAR1FFAR4 | |
| SCHEMBL11967105 | 0.76 | GPR84 (0.59) | GPR84FFAR1FFAR4 | |
| Stearic Acid SCHEMBL27603252 | 0.76 | FFAR4 (0.79) | GPR84FFAR1FFAR4PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | claimed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | claimed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | claimed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | claimed |
| US-8148321-B2 | Bioconjugates as therapeutic agent and synthesis thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2009-04-02 | — | — | US | disclosed |
| EP-1996236-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | National Institute of Immunology (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007108013-A2 | NOVEL BIOCONJUGATES AS THERAPEUTIC AGENT AND SYNTHESIS THEREOF | NATIONAL INSTITUTE OF IMMUNOLOGY (IN) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088372-A1 | Novel Bioconjugates As Therapeutic Agent and Synthesis Thereof | DNPEP, LNPEP, RNPEP | GPR84 945/4885FFAR1 1146/4885FFAR4 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.